Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Feb;30(2):239-244.
doi: 10.1007/s00192-018-3640-4. Epub 2018 Mar 29.

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Affiliations
Randomized Controlled Trial

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Howard B Goldman et al. Int Urogynecol J. 2019 Feb.

Abstract

Introduction and hypothesis: We sought to determine whether baseline characteristics predict which overactive bladder (OAB) patients benefit from fesoterodine 8 mg versus 4 mg.

Methods: In double-blind, placebo-controlled, flexible-dose trials, baseline characteristics of OAB patients with ≥ 1 urgency urinary incontinence (UUI) episodes/24 h who escalated from fesoterodine 4 mg to 8 mg were evaluated. Possible dose-escalation predictors (age; sex; previous antimuscarinic use; UUI, micturitions, and urgency episodes/24 h; race; body mass index; time to dose escalation; OAB duration) were compared in escalators versus non-escalators. Patients from fixed-dose trials with dose-escalator characteristics were identified (matched dose-escalator sample) to assess changes from baseline with fesoterodine 4 mg, 8 mg, and placebo.

Results: In flexible-dose trials, significant predictors of fesoterodine dose escalation were younger age (≤ 65.8 years), greater number of baseline micturitions (≥ 13.1) and urgency episodes/24 h (≥ 10.9), greater OAB duration (≥ 9.1 years), and more frequent previous antimuscarinic use (58.3%), but not baseline UUI episodes/24 h. In the matched dose-escalator sample (fesoterodine 4 mg: n = 215; 8 mg: n = 198; placebo: n = 217), change from baseline in UUI episodes significantly improved with fesoterodine 8 mg versus 4 mg (P = 0.043) and with both doses versus placebo (P < 0.001). Dry mouth and constipation rates were higher with fesoterodine 8 mg.

Conclusions: Dose-escalator patients had a significantly greater UUI response with fesoterodine 8 mg versus 4 mg. Given the potential for adverse events, fesoterodine 4 mg is recommended to start; however, patients with UUI and identified predictors may benefit from initial treatment with fesoterodine 8 mg or rapid dose escalation.

Keywords: Dose-response relationship, drug; Fesoterodine; Randomized-controlled trials; Urinary bladder, overactive; Urinary incontinence, urge.

PubMed Disclaimer

References

    1. World J Urol. 2003 May;20(6):327-36 - PubMed
    1. Value Health. 2004 Jul-Aug;7(4):455-63 - PubMed
    1. Eur Urol. 2007 Oct;52(4):1204-12 - PubMed
    1. J Urol. 2007 Dec;178(6):2488-94 - PubMed
    1. Urology. 2008 May;71(5):839-43 - PubMed

Publication types

LinkOut - more resources